End-stage Heart Failure Clinical Trial
— SweVADOfficial title:
Swedish Evaluation of Left Ventricular Assist Device
NCT number | NCT02592499 |
Other study ID # | ver 6.0 |
Secondary ID | 635-14 |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | December 2025 |
The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. Eighty (80) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM, based on a modified power calculation.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 2025 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent 2. Adult (= 18 years) 3. Chronic heart failure = 45 days or stable not supported by mechanical circulatory support since >7days on single inotrope. 4. Left ventricular ejection fraction = 30%. 5. NYHA IIIB-IV, INTERMACS profile 2-6 6. At least 2 of 4 adverse prognostic criteria: - SHFM estimated 1-year survival =75% - NTproBNP = 2000 ng/l - VO2 max < 14 ml/kg/min or <50% of predicted VO2max with attainment of anaerobic threshold (AT), or unable to perform. - Need for continuous or intermittent inotropic support or >2 hospitalizations during last 6 months. 7. Receiving medical management with optimal doses of betablockers, ACE-inhibitors or ARBs, and MRAs for at least 30 days if tolerated. 8. Receiving CRT if indicated for at least 45 days. 9. Receiving ICD if indicated and appropriate. 10. Ineligible for cardiac transplantation (e.g. high age and/or co-morbidities) 11. Considered suitable for the study by a multidisciplinary board Exclusion Criteria: 1. Eligible for heart transplantation or is likely to become eligible after VAD treatment (bridge-to-candidacy) 2. Indication for revascularisation, valvular surgery or other cardiac intervention expected to improve cardiac function and prognosis (CABG, PCI TAVI, mitraclip etc.) 3. INTERMACS profile 1 "crash and burn" 4. On-going mechanical circulatory support. 5. Heart failure due to restrictive cardiomyopathy pericardial disease, active myocarditis or uncorrected thyroid disease. 6. Mechanical aortic valve that will not be converted to a bioprosthesis or patch 7. Moderate to severe aortic insufficiency without plans for correction 8. Technical obstacles, which pose an inordinately high surgical risk 9. Active, uncontrolled infection 11. Stroke within 90 days or carotid artery stenosis > 80 % 12. Significant vascular disease. 13. Severe COPD or severe restrictive lung disease. 14. Intrinsic hepatic disease as defined by liver enzyme values (AST or ALT or total bilirubin) > 5 times the upper limit of normal, or INR > 2.0, which is not due to anti-coagulant therapy. 15. Intolerance to anticoagulant or antiplatelet therapies or any other operative therapy the patient will require based upon the patient's health status. 16. Platelet count < 50,000. 17. Measured GFR <20 ml/min/1.73m2 unresponsive to inotrope treatment or chronic dialysis. 18. High risk for right ventricular failure according to echocardiography and/or invasive hemodynamic measurements as judged by the investigator (>2 parameter constitute an exclusion criteria) using a combination of the: a. Severe TI b. TAPSE < 0.72 cm c. RVEDD/LVEDD > 0.72 d. CVP > 16 mm Hg e. MPAP - RAP < 10 mmHg SPAP-DPAP/CVPm >1 ok, <0.5 very bad, in between borderline f. CVP/PCWP > 0.63 g. RVSWI < 300 mm Hg x ml/m2 h. Bilirubin > 34 micromol/L 19. Body Mass Index (BMI) > 42 kg/m2. 20. Psychiatric disease, cognitive dysfunction, alcohol or drug abuse, or psychosocial issues that are likely to impair study compliance 21. Female of childbearing age with a positive pregnancy test or not willing to use adequate contraceptive precautions during the study. 22. Condition, other than heart failure, that could limit survival to less than 2 years. |
Country | Name | City | State |
---|---|---|---|
Sweden | Sahlgrenska Univesitetssjukhustet, Transplantationscentrum | Gothenburg | |
Sweden | Linköping Univ Hospital | Linköping | |
Sweden | Skåne University Hospital | Lund | |
Sweden | Örebro Univ Hospital | Örebro | |
Sweden | Karolinska Univ Hospital | Stockholm | |
Sweden | Univ Hospital of Umeå | Umeå | |
Sweden | Uppsala Univ Hospital | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Vastra Gotaland Region | Karolinska University Hospital, Region Örebro County, Skane University Hospital, University Hospital, Linkoeping, University Hospital, Umeå, Uppsala University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival at two years of follow-up | survival | 2 years, | |
Secondary | Number of participants free from disabling stroke during the 2-year follow-up period | Survival free from disabling stroke (Modified Rankin Scale (MRS) >3) | 2 years | |
Secondary | A composite endpoint of "survival free from disabling stroke", survival and non-planned hospitalizations | Survival free from a composite endpoint of disabling stroke, survival and non-planned hospitalizations | 2 years | |
Secondary | Survival at year of follow-up | Survival at year | 1 year | |
Secondary | Functional capacity (NYHA) during the 2-year follow-up period | functional capacity determined by NYHA classification | 2 years | |
Secondary | Functional capacity (6 min walk-test) during the 2-year follow-up period | functional capacity determined by 6 min walk-test | 2 years | |
Secondary | Functional capacity (peak VO2) | functional capacity determined by peak VO2 | 2 years | |
Secondary | Health-related quality of Life during the 2-year follow-up period | Health-related quality of Life asses with EQ-5D-5L, SF-36 and KCCQ | 2 years | |
Secondary | Number of participants with heart-failure related events | 2 years | ||
Secondary | Cost-effectiveness during the 2-year follow-up period | Cost effectiveness calculated with QUALY (Quality-adjusted Life-year) and LY (Life year) | 2 years | |
Secondary | Renal function during the 2-year follow-up period | Glomerular filtration rate evaluated by 51 chrome-EDTA or Iohexol clearance | 2 years | |
Secondary | Hospital admissions during the 2-year follow-up period | Number of hospital admissions | 2 years | |
Secondary | Number of participants with serious adverse events (SAEs) | 2 years | ||
Secondary | Functional capacity (peak VO2) | functional capacity determined by peak VO2 | 1 year | |
Secondary | Three-years survival | survival | 3 years | |
Secondary | Four-years survival | survival | 4 years | |
Secondary | Five-years survival | survival | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06063811 -
Ventricular Tachycardia Ablation in LVAD Patients
|
||
Withdrawn |
NCT04782245 -
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
|
Phase 2 | |
Active, not recruiting |
NCT04351945 -
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
|
||
Recruiting |
NCT03966313 -
Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation
|
||
Active, not recruiting |
NCT00490321 -
VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
|
Phase 3 | |
Active, not recruiting |
NCT00483197 -
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
|
Phase 3 | |
Completed |
NCT04543747 -
Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
|
||
Recruiting |
NCT04293575 -
Transcatheter Mitral Valve Repair as Bridge Therapy to Heart Transplantation
|
||
Recruiting |
NCT04641416 -
Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps
|
||
Completed |
NCT00490347 -
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
|
Phase 2 | |
Suspended |
NCT04117295 -
Carmat TAH Early Feasibility Study
|
N/A | |
Completed |
NCT05353816 -
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
|
N/A | |
Completed |
NCT04480151 -
ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)
|
||
Recruiting |
NCT04205760 -
Preoperative Nutritional Optimization and Physical Exercise for Patients Scheduled for Elective Implantation for a Left-Ventricular Assist Device
|
Phase 3 | |
Recruiting |
NCT06345521 -
Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
|
||
Recruiting |
NCT04768322 -
LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients
|
N/A | |
Completed |
NCT02248974 -
Development & Testing of a Decision Aid for LVAD Placement
|
N/A | |
Completed |
NCT06152562 -
Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
|
||
Completed |
NCT05928273 -
Corheart 6 LVAS LTFU
|
N/A | |
Recruiting |
NCT04951999 -
AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support
|
N/A |